NUMARZU-001

N/A

Report date: 2022/07/22 15:44:52

Base Information

Drug NameNUMARZU-001

Drug Alias NamePD1+ TILs (NUMARZU-001)Adoptive Therapy of PD1+ TILS (TILS001 Trial)TILsNUMARZU-001

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Tumor Infiltrating Lymphocytes

Mechanisms of ActionUpdating

TargetsUpdating

Therapy Area/IndicationsTriple Negative Breast Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySpain

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesFundacio Clinic Barcelona

China Registration ClassN/A

Develop Information

Active CompaniesFundacio Clinic Barcelona

Inactive CompaniesN/A

Active IndicationsTriple Negative Breast Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A